Market Data 
Markets
Replies to post #11266 on Imaging Diagnostic Systems (fka IMDS)
06/22/12 9:55 AM
In fiscal 2010, fiscal 2011, fiscal 2012 and thus far in fiscal 2013, we have used the proceeds from short-term loans, long-term loans and proceeds from our Southridge Private Equity Credit Agreement for working capital. Going forward we intend to use the proceeds from short term and long term loans and issuance of convertible preferred stock, as our sources of working capital. We may also seek to raise fund through our Private Equity Credit Agreement with Southridge which requires an effective S-1 Registration Statement. Substantial additional financing will be required before and after receipt of FDA marketing clearance, assuming it is received, as to which there can be no assurance.
Devcool
Friday, June 22, 2012 9:48:46 AM
Re: ~ Blue ~ post# 11263
Post # of 29580
6 REASONS WHY IMDS WILL BE TRADING AT $5-10/SHARE IN A YEAR:
- 35 patents capable of GLOBAL monopoly. 20 USA and 15 INTL. JUST 1 of their patents accounts for the CTLM's ability to detect cancer through dense tissue and implants...NO OTHER TECHNOLOGY IN THE WORLD CAN DO THIS! Dense tissue extends into the brain, lungs, etc. and therefore the laser optical imaging technology will be enhancing virtually ALL aspects of the medical diagnostics field!
- 16 distributors in 16 countries ALREADY...not to mention pending Russia approval! They also have FDA EXPORT CERTIFICATION, CE MARKETING (32 countries in Europe), and CHINA approval
- Shimadzu Medical signed on as a distributor, and JUST YESTERDAY updated their website confirming business relationships
http://www.shimadzumedical.com.au/imaging-diagnostic-distribution-agreement-.html
- Each CTLM sells at a retail price of $495,000 each...the product will monopolize the global mammography market.
- Upon securing non-toxic funding, the company will be immediately applying to the FDA, and the approval will be received BEFORE the usual 90 day review window. During this period, there will most likely be immediate distribution through Shimadzu Medical to New Zealand and the Pacific Islands. Distribution to Australia will occur as soon as possible as well, and stockprince's email with the company showed that the application to Australia for approval of the CTLM has ALREADY BEEN SUBMITTED BY SHIMADZU MEDICAL OCEANIA...before the FDA process is even complete you're looking at MULTI-MILLIONS on revenue that should be apparent on the Q2.
- The breast mammogram market in the USA is controlled by only 4 COMPANIES!! ALL WITH DATED TECHNOLOGY, AND HAZARDOUS!! THE CTLM DOESN'T USE X-RAYS or any other hazardous particle, and no longer needs to squeeze the breast. YOU'RE LOOKING AT PATIENT SATISFACTION, SAFETY, and NO UN-NEEDED BIOPSIES as it has been CLINICALLY PROVEN the CTLM is up to 90% more effective than anything on the market TODAY!
"In a study of over 100 women, including 30 with breast cancer, optical imaging increased sensitivity and specificity of breast cancer detection by more than 90% (Britton Chance, Molecular Imaging, Vol. 2 #2)"
http://www.imds.com/ctlm/
There are 10,000 mammogram centers in the USA alone, each machine sells at a retail price of $495,000 each...now...think of the rest of the world and you do the math $5-10/share in a year folks, in the first year alone IMDS will exceed a billion in revenue
11/20/12 12:33 PM
Devcool Friday, June 22, 2012 9:48:46 AM
Re: ~ Blue ~ post# 11263
Post # of 30956
6 REASONS WHY IMDS WILL BE TRADING AT $5-10/SHARE IN A YEAR:
- 35 patents capable of GLOBAL monopoly. 20 USA and 15 INTL. JUST 1 of their patents accounts for the CTLM's ability to detect cancer through dense tissue and implants...NO OTHER TECHNOLOGY IN THE WORLD CAN DO THIS! Dense tissue extends into the brain, lungs, etc. and therefore the laser optical imaging technology will be enhancing virtually ALL aspects of the medical diagnostics field!
- 16 distributors in 16 countries ALREADY...not to mention pending Russia approval! They also have FDA EXPORT CERTIFICATION, CE MARKETING (32 countries in Europe), and CHINA approval
- Shimadzu Medical signed on as a distributor, and JUST YESTERDAY updated their website confirming business relationships
http://www.shimadzumedical.com.au/imaging-diagnostic-distribution-agreement-.html
- Each CTLM sells at a retail price of $495,000 each...the product will monopolize the global mammography market.
- Upon securing non-toxic funding, the company will be immediately applying to the FDA, and the approval will be received BEFORE the usual 90 day review window. During this period, there will most likely be immediate distribution through Shimadzu Medical to New Zealand and the Pacific Islands. Distribution to Australia will occur as soon as possible as well, and stockprince's email with the company showed that the application to Australia for approval of the CTLM has ALREADY BEEN SUBMITTED BY SHIMADZU MEDICAL OCEANIA...before the FDA process is even complete you're looking at MULTI-MILLIONS on revenue that should be apparent on the Q2.
- The breast mammogram market in the USA is controlled by only 4 COMPANIES!! ALL WITH DATED TECHNOLOGY, AND HAZARDOUS!! THE CTLM DOESN'T USE X-RAYS or any other hazardous particle, and no longer needs to squeeze the breast. YOU'RE LOOKING AT PATIENT SATISFACTION, SAFETY, and NO UN-NEEDED BIOPSIES as it has been CLINICALLY PROVEN the CTLM is up to 90% more effective than anything on the market TODAY!
"In a study of over 100 women, including 30 with breast cancer, optical imaging increased sensitivity and specificity of breast cancer detection by more than 90% (Britton Chance, Molecular Imaging, Vol. 2 #2)"
http://www.imds.com/ctlm/
There are 10,000 mammogram centers in the USA alone, each machine sells at a retail price of $495,000 each...now...think of the rest of the world and you do the math big smile $5-10/share in a year folks, in the first year alone IMDS will exceed a billion in revenue
AI
